Search TRAW
Traws Pharma, Inc.
Nasdaq · CIK 1130598
Last close0.57
Daily change+0.02 (3.64%)
10 Years gain-100.00%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TRAW · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
85.0Momentum
n/aAcceleration
n/aConfidence
62.0Annual Revenue15
Quarterly Revenue49
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality12.5 / 25
Capital Efficiency18.3 / 20
Balance Sheet15.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Heavy share dilution · HIGHDiluted share count increased 591.5338%.
Key Metrics
Revenue Growth TTM1,184.96%OK
Revenue CAGR 3Y131.12%OK
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y591.53%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 FY Dec 31, 2025 | $2.79M | $2.79M | -$17.88M | -$18.19M | -$20.77M | 100% | -640.68% | -744.44% | n/a | 8.38M |
| 2024 FY Dec 31, 2024 | $226,000.00 | $226,000.00 | -$142.37M | -$29.79M | -$33.44M | 100% | -62,997.35% | -14,796.46% | n/a | 1.55M |
| 2024 FY Dec 31, 2023 | $226,000.00 | $226,000.00 | -$20.30M | -$17.93M | -$17.95M | 100% | -8,981.42% | -7,940.71% | n/a | 839,554 |
| 2023 FY Dec 31, 2022 | $226,000.00 | $226,000.00 | -$19.63M | -$16.29M | n/a | 100% | -8,684.51% | n/a | n/a | 20.91M |
| 2022 FY Dec 31, 2021 | $226,000.00 | $226,000.00 | -$16.50M | -$19.49M | n/a | 100% | -7,299.12% | n/a | n/a | 16.83M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $2.90M | sum latest 4 fiscal quarters Revenue | OK | 0001558370-25-011469, 0001558370-24-015752 |
| Revenue Growth TTM | 1,184.96% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001558370-25-011469, 0001558370-24-015752 |
| Revenue CAGR 3Y | 131.12% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-043832 |
| Revenue CAGR 5Y | 64.59% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001104659-26-043832 |
| Gross Profit CAGR 3Y | 131.12% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001104659-26-043832 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001104659-26-097261 |
| Current Ratio | 2.09x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.50 | Revenue / Diluted Shares | OK | 0001558370-25-011469, 0001558370-24-015752 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001104659-26-043832 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | 0001104659-26-097261 |
| Gross Margin Delta 1Y | n/a | GrossMargin_current - GrossMargin_prior_year | INSUFFICIENT_HISTORY | derived |